Evolution of tumour cells during AsiDNA treatment results in energy exhaustion, decrease of responsiveness to signal and higher sensitivity to the drug - Institut Curie Accéder directement au contenu
Article Dans Une Revue Evolutionary Applications Année : 2020

Evolution of tumour cells during AsiDNA treatment results in energy exhaustion, decrease of responsiveness to signal and higher sensitivity to the drug

Résumé

It is increasingly suggested that ecological and evolutionary sciences could inspire novel therapies against cancer but medical evidence of this remains scarce at the moment. The Achilles heel of conventional and targeted anticancer treatments is intrinsic or acquired resistance following Darwinian selection, i.e. treatment toxicity places the surviving cells under intense evolutionary selective pressure to develop resistance. Here, we review a set of data that demonstrate that Darwinian principles derived from the “smoke detector” principle can instead drive the evolution of malignant cells toward a different trajectory. Specifically, long term exposure of cancer cells to a strong alarm signal, generated by the DNA repair inhibitor AsiDNA, induces a stable new state characterized by a down‐regulation of the targeted pathways and does not generate resistant clones. This property is due to the original mechanism of action of AsiDNA, which acts by over‐activating a “false” signaling of DNA damage through DNA‐PK and PARP enzymes, and is not observed with classical DNA repair inhibitors such as the PARP inhibitors. Long‐term treatment with AsiDNA induces a new “alarm down” state in the tumor cells with decrease of NAD level and reactiveness to it. These results suggest that agonist drugs such as AsiDNA could promote a state‐dependent tumor cell evolution by lowering their ability to respond to high “danger” signal. This analysis provides a compelling argument that evolutionary ecology could help drug design development in overcoming fundamental limitation of novel therapies against cancer due to the modification of the targeted tumor cell population during treatment.
Fichier principal
Vignette du fichier
eva.12949.pdf (911.76 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-02527629 , version 1 (23-11-2021)

Licence

Paternité

Identifiants

Citer

Pierre‐marie Girard, Nathalie Berthault, Maria Kozlac, Sofia Ferreira, Wael Jdey, et al.. Evolution of tumour cells during AsiDNA treatment results in energy exhaustion, decrease of responsiveness to signal and higher sensitivity to the drug. Evolutionary Applications, 2020, ⟨10.1111/eva.12949⟩. ⟨hal-02527629⟩
60 Consultations
32 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More